Clinical trials: Advanced Solid Tumors Cancer
Cancer
OLAParib COmbinations
The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
- Trial name
- OLAPCO (NCT02576444)
- Testing
- AZD2281, AZD5363, AZD1775
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- Joseph Paul Eder
Neoplasms
Study of IMC-11F8 in Participants With Advanced Solid Tumors
This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded…
- Trial name
- NCT01088464
- Testing
- IMC-11F8
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
This is an open-label, cohort study to determine the feasibility and tolerability of the combination of TAK-228 and TAK-117 given on days 2-4, 9-11, 16-18, and 23-25 with paclitaxel on days 1, 8, and 15 for one 28-day cycle in…
- Trial name
- NCT03154294
- Testing
- paclitaxel, TAK-228, TAK-117
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor
A Study of EMD525797 in Solid Tumor Patients in Japan
The primary objectives are to assess the safety and tolerability of single and repeated doses of EMD525797, and characterize Pharmacokinetics (PK).
- Trial name
- NCT01327313
- Testing
- EMD525797
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced).
- Trial name
- NCT04171219
- Testing
- Pembrolizumab, Talabostat Mesylate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Bladder Cancer, Triple-negative Breast Cancer
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
- Conditions
- Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02527434
- Testing
- Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors
Oral Bioavailability and Mass Balance Trial With Pimasertib
This is a Phase 1, open-label, single centered trial to evaluate the mass balance, bioavailability and metabolism of pimasertib in cancer subjects with locally advanced or metastatic solid tumors.
- Trial name
- NCT01713036
- Testing
- Pimasertib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neoplasms, Breast Neoplasms
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part. The dose escalation part is open-label, and evaluates safety, preliminary efficacy and PK of single-agent talazoparib in sequential…
- Trial name
- NCT03343054
- Testing
- talazoparib
- Where
- 8 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Pfizer
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Ovarian Neoplasms, Endometrial Neoplasms
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18 years of age with advanced or metastatic…
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms
- Trial name
- C4431001 (NCT05067972)
- Testing
- PF-07260437, B7-H4 IHC
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
The Primary Phase I objectives are to determine the recommended phase II dose for the capecitabine and aflibercept doublet combination; and to describe any dose limiting and non-dose limiting toxicities.
- Trial name
- X-TRAP (NCT01661972)
- Testing
- Capecitabine and aflibercept
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- John Strickler, M.D.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06357975
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer
- Trial name
- NCT01975831
- Testing
- Durvalumab, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ludwig Institute for Cancer Research
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Solid Tumors
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor.
- Trial name
- NCT03745989
- Testing
- MK-8353, Selumetinib
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Endometrial Adenocarcinomas, Neuroendocrine Tumors
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose…
- Conditions
- Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
- Trial name
- NCT01970540
- Testing
- lurbinectedin (PM01183), Doxorubicin
- Where
- 7 sites in Spain, United Kingdom
- Volunteers
- 122 people
- Sponsor
- PharmaMar
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer